Meeting
2019 ASCO Annual Meeting
WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).
Authors
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD
Pedro Isaacsson Velho , Nooshin Mirkheshti , Fahad Qazi , Farah Shaukat , Wei Fu , Hao Wang , Michael Anthony Carducci , Mark Christopher Markowski , Samuel R. Denmeade , Catherine Handy Marshall , Tamara L. Lotan , Mario A. Eisenberger , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5068)
DOI
10.1200/JCO.2019.37.15_suppl.5068
Abstract #
5068
Poster Bd #
180
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Characterization and impact of canonical Wnt Signaling Pathway (WSP) alterations on outcomes of metastatic prostate cancer.
First Author: Rana R. McKay
Poster
2023 ASCO Genitourinary Cancers Symposium
Clinical implications of Wnt signaling alterations in patients (pts) with advanced prostate cancer (aPC).
First Author: Amanda Broderick
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Daniel Joseph Khalaf
Poster
2021 Genitourinary Cancers Symposium
SPOP mutations in prostate cancer: Clinical and genomic features.
First Author: Mari Nakazawa